Entera Bio (ENTX) Projected to Post Earnings on Friday

Entera Bio (NASDAQ:ENTX) is anticipated to issue its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect Entera Bio to post earnings of ($0.09) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 30, 2026 at 6:30 AM ET.

Entera Bio Trading Up 14.6%

Shares of ENTX opened at $1.18 on Thursday. The company’s 50 day simple moving average is $1.40 and its 200-day simple moving average is $1.90. The firm has a market cap of $54.11 million, a PE ratio of -4.72 and a beta of 1.83. Entera Bio has a 12-month low of $0.98 and a 12-month high of $3.22.

Analyst Ratings Changes

ENTX has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a research note on Saturday, December 27th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Entera Bio in a research note on Monday, February 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $10.00.

Insider Activity

In related news, Director Geno J. Germano purchased 20,000 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was acquired at an average price of $1.30 per share, for a total transaction of $26,000.00. Following the completion of the purchase, the director directly owned 40,000 shares of the company’s stock, valued at $52,000. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased a total of 69,000 shares of company stock valued at $92,530 over the last quarter. Insiders own 10.38% of the company’s stock.

Hedge Funds Weigh In On Entera Bio

Hedge funds and other institutional investors have recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC raised its position in Entera Bio by 5.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after buying an additional 29,629 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after acquiring an additional 19,601 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after acquiring an additional 43,536 shares in the last quarter. HighTower Advisors LLC increased its stake in shares of Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after acquiring an additional 25,000 shares during the period. Finally, Citadel Advisors LLC increased its stake in shares of Entera Bio by 243.0% during the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after acquiring an additional 28,322 shares during the period. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio, Inc is a clinical?stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.